Patient and Practice-Level Barriers in Limited-Stage SCLC Care

This episode, "Patient and Practice-Level Barriers in Limited-Stage SCLC Care," turns from clinical decision-making to the everyday logistics that can make or break treatment completion.

This episode extends the conversation about barriers to consolidation immunotherapy in limited-stage small cell lung cancer, shifting focus from clinical decision-making to the logistical realities patients face. Distance from treatment centers surfaces repeatedly as a practical obstacle: patients who live far from a facility may need temporary housing to complete daily radiation, and the same distance becomes a burden again once monthly durvalumab infusions begin. The panel describes patients who, after a few cycles, find the travel unsustainable, prompting efforts to connect them with more local infusion options or to space out follow-up visits, such as scans every three months instead of more frequently, to reduce the overall burden.

The discussion broadens to acknowledge that support resources exist to help patients manage these challenges, even though they cannot fully eliminate them. Beyond patient-facing barriers, the panel turns to what physicians and practices can do differently. Rather than relying on individual clinicians to remember to order consolidation therapy as a separate step, building it directly into treatment pathways, order sets, and electronic medical record workflows is proposed as a systems-level fix. Embedding consolidation immunotherapy into the default care pathway, rather than treating it as an optional add-on that depends on memory, is framed as a way to make the right next step the easy next step.

The episode closes by tying these systems-based solutions back to the broader theme of the series: that closing the gap between trial efficacy and real-world uptake requires attention not just to individual patient circumstances, but to the infrastructure and defaults that shape everyday clinical decision-making across a practice.

The next episode, "Limited-Stage SCLC: Unmet Needs and Emerging Biomarkers," has the panel taking stock of what still remains unresolved in limited-stage disease.